GSK3B and Alzheimer disease: Additionally, WB demonstrated that, with the increase of GSK3β, the expression of Wnt and β‐catenin in the AD group was lower than that in the control group; however, the decrease of β‐catenin did not differ from that in the control group (*p < 0.05, p > 0.05) (Figure 7D,E).